Taurolidine

製品コードS4885 バッチS488501

印刷

化学情報

Chemical Structure Synonyms Taurolin, Tauroline, Tauroflex Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C7H16N4O4S2
分子量 284.36 CAS No. 19388-87-5
Solubility (25°C)* 体外 DMSO 56 mg/mL (196.93 mM)
 
 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Taurolidine (Taurolin, Tauroline, Tauroflex) is a synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities.
in vitro Taurolidine inhibits the growth of a rat metastatic colorectal tumor cell line in vitro[1]. Taurolidine possesses antineoplastic activity. The antiproliferative IC50 of taurolidine is in the 10-50 μM range, approximately 100-fold lower that that required for its antibiotic effects. Exposure to taurolidine induces apoptosis in SKOV-3 and PA-1 human tumor cells but apparently not in NIH-3T3 fibroblasts[2]. Taurolidine causes significant in vitro growth inhibition and cytotoxicity of human MM cells, which appears to be due, at least in part, to apoptosis[3].
in vivo In BD IX rats that underwent laparotomy, intraperitoneal instillation of DHD/K12/TRb tumor cells, local/intraperitoneal administration of taurolidine results in a marked decrease in tumor burden compared with control animals[1]. The i.p. administration of taurolidine effectively inhibits the development and growth of ovarian tumors when therapy is initiated on the day of tumor cell injection[2]. i.p. taurolidine inhibits adherence of colon tumor cells injected into the peritoneal cavity of rats[3].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 a rat metastatic colorectal tumor cell line (DHD/K12/TRb)
濃度 5, 10, 15, 25 mg/ml
反応時間 14 h
実験の流れ DHD/K12/TRb cells (1×105 cells/ml) are cultured in 24-well plates and incubated for 6 hours at 37°C in humidified 5% CO2 conditions to allow the cells to adhere. Culture medium is then removed and fresh culture medium alone (control) or culture medium with 5, 10, 15, and 25 mg/ml of Taurolidine is added. Cells are then incubated at 37°C in humidified 5% CO2 conditions for a further 14 hours followed by addition of 10 ml of BrdU labeling solution.
動物実験 動物モデル Adult male syngenic BD IX rats, aged 8-10 weeks
投薬量 100 mg/kg
投与方法 i.p.

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。